COVID-19 And Lingering Symptoms In Primary Care Patients (CALIP)

The ongoing corona virus disease 2019 (COVID-19) is a viral acute respiratory tract infection caused by server acute respiratory syndrom coronavirus typ 2 (SARS-CoV-2). The signs and symptom of SARS-CoV-2 infection vary and most people with COVID-19 experience illness of mild or moderate severity and recover with symptomatic treatment outside of hospital. Studies have found that some people experience lingering/long-lasting symptoms and only a minority of patients were completely free from COVID-19 related symptoms after two months. About one third still had up to two residual symptoms and 55% had three or more. As far as we know no study on lingering symptoms has been published in patients after a mild or moderate infection managed in primary care settings. The aim of this study is to explore the course of disease over a one year period and describe lingering symptoms and their impact on well-being and daily activities in adult non-hospitalized patients with previous established COVID-19 infection.

Study Overview

• Status: Completed
• Conditions: Covid19; Symptoms and Signs

• Study Type: Observational
• Enrollment (Actual): 300

Contacts and Locations

Study Locations

• Belgium
  • Antwerp, Belgium
    • Centre for General Practice, Department of Family Medicine & Population Health (FAMPOP), Faculty of Medicine and Health Sciences, University of Antwerp
  • Leuven, Belgium
    • the Academic Centre for General Practice (ACHG), Department of Public Health and Primary Care, KU Leuven
• Denmark
  • Aalborg, Denmark
    • Center for General Practice at Aalborg University
• France
  • Nice, France
    • Département de Santé Publique, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
• Georgia
  • Tbilisi, Georgia
    • R. Lugar Center for Public Health Research
• Germany
  • Würzburg, Germany
    • Institut für Allgemeinmedizin Universitätsklinikum Würzburg Josef-Schneider-Str. 2/D7 97080 Würzburg
• Ireland
  • Galway, Ireland
    • School of Medicine, National University of Ireland
• Italy
  • Modena, Italy
    • Covid-19 primary care special unit Sassuolo, Azienda Unità Sanitaria locale di Modena, Modena, Italy
• Netherlands
  • Utrecht, Netherlands
    • Julius Center, University Medical Center Utrecht
• Poland
  • Lodz, Poland
    • Medical University of Lodz, Lodz
• Romania
  • Cluj-Napoca, Romania
    • Balan Medfam SRL
• Sweden
  • Jönköping, Sweden
    • Wetterhälsan Primary Health Care Centre
  • Linköping, Sweden
    • Kärna Primary Health Care Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Adult patients over all age categories with laboratory confirmed SARS-CoV-2 infection and symptoms consistent with COVID-19

Description

Inclusion Criteria:

• Confirmed SARS-CoV-2 infection, either by polymeras chain reaction (PCR), or by antigen testing (if authorized/recommended/used by national/local governments)
• Symptoms consistent with mild to moderate COVID-19
• Maximum of 2 weeks since positive SARS-CoV-2 test
• Aged 18 years and older
• Patient able and willing to comply with monthly phone calls.

Exclusion Criteria:

• Hospitalisation due to COVID-19

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to full recovery symptoms	Number of weeks until "back to normal"	through study completion, a maximum of 1 year

Collaborators and Investigators

• Sponsor: Katarina Hedin
• Collaborators: National University of Ireland, Galway, Ireland; Region Jönköping County; Utrecht University; Research Unit for General Practice in Aalborg
• Investigators: Principal Investigator: Katarina Hedin, Assoc Prof, Region Jönköping County Sweden

Study record dates

Study Major Dates

• Study Start (Actual): December 12, 2020
• Primary Completion (Actual): June 30, 2022
• Study Completion (Actual): June 30, 2022

Study Registration Dates

• First Submitted: March 7, 2021
• First Submitted That Met QC Criteria: March 23, 2021
• First Posted (Actual): March 24, 2021

Study Record Updates

• Last Update Posted (Estimated): September 4, 2025
• Last Update Submitted That Met QC Criteria: August 27, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; Pathological Conditions, Signs and Symptoms; COVID-19; Signs and Symptoms
• Other Study ID Numbers: 2020-05448

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No